S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
"Prepare for Five Years of Famine" (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
"Prepare for Five Years of Famine" (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
"Prepare for Five Years of Famine" (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
"Prepare for Five Years of Famine" (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
The Day of Financial Reckoning Is Near (Ad)
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$78.66
+1.20 (+1.55%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$76.39
$80.11
50-Day Range
$55.27
$83.78
52-Week Range
$42.51
$135.70
Volume
903,046 shs
Average Volume
1.38 million shs
Market Capitalization
$6.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.33

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
42.8% Upside
$112.33 Price Target
Short Interest
Bearish
15.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of CRISPR Therapeutics in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$3.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.20) to ($7.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

299th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

50th out of 175 stocks

CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Therapeutics Stock Up 1.5 %

CRSP Stock opened at $78.66 on Friday. CRISPR Therapeutics has a one year low of $42.51 and a one year high of $135.70. The firm has a 50-day moving average of $72.48 and a two-hundred day moving average of $63.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.40) EPS for the quarter, missing analysts' consensus estimates of ($2.21) by ($0.19). The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $2.20 million. CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative return on equity of 27.40%. CRISPR Therapeutics's quarterly revenue was down 100.0% compared to the same quarter last year. During the same period in the prior year, the company posted $9.44 earnings per share. As a group, equities research analysts predict that CRISPR Therapeutics will post -9.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Credit Suisse Group increased their target price on shares of CRISPR Therapeutics from $74.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday. SVB Leerink decreased their target price on shares of CRISPR Therapeutics from $112.00 to $107.00 and set an "outperform" rating for the company in a research report on Monday, August 8th. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $52.00 to $46.00 and set a "neutral" rating for the company in a research report on Tuesday, May 24th. BMO Capital Markets assumed coverage on shares of CRISPR Therapeutics in a research report on Thursday, June 16th. They issued an "outperform" rating and a $98.00 target price for the company. Finally, Barclays lowered shares of CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $99.00 to $88.00 in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.31.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares of the company's stock, valued at $22,035,078.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.70% of the stock is owned by insiders.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

MarketBeat: Week in Review 8/1 - 8/5 (CRSP)
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment
Cathie Wood Dumped These 7 Stocks in July
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
8/08/2022
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$112.33
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$46.00
Forecasted Upside/Downside
+42.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$377.66 million
Net Margins
-4,274.02%
Pretax Margin
-4,227.61%

Debt

Sales & Book Value

Annual Sales
$914.96 million
Cash Flow
$5.44 per share
Book Value
$26.80 per share

Miscellaneous

Free Float
69,662,000
Market Cap
$6.14 billion
Optionable
Optionable
Beta
1.93














CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2022?

16 brokers have issued 1-year target prices for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $46.00 to $220.00. On average, they anticipate the company's share price to reach $112.33 in the next year. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2022?

CRISPR Therapeutics' stock was trading at $75.78 at the beginning of 2022. Since then, CRSP stock has increased by 3.8% and is now trading at $78.66.
View the best growth stocks for 2022 here
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Monday, August, 8th. The company reported ($2.40) EPS for the quarter, missing analysts' consensus estimates of ($2.21) by $0.19. The company earned $0.20 million during the quarter, compared to analysts' expectations of $2.20 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,274.02%. The company's revenue was down 100.0% compared to the same quarter last year. During the same period last year, the firm posted $9.44 EPS.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.92%), Nikko Asset Management Americas Inc. (5.92%), FMR LLC (2.08%), Loomis Sayles & Co. L P (1.80%), Credit Suisse AG (1.18%) and Renaissance Technologies LLC (0.73%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $78.66.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $6.14 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.23) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.